Standard Biotools (LAB) Consolidated Net Income (2010 - 2026)

Standard Biotools (LAB) has reported Consolidated Net Income for 17 consecutive years, with -$26.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Consolidated Net Income rose 20.0% year-over-year to -$26.8 million in Q2 2026; TTM through Jun 2026 was $84.9 million, a 184.1% increase from a year earlier, with the FY2025 full-year figure at -$74.9 million, up 37.25% from the prior year.
• Consolidated Net Income was -$26.8 million for Q2 2026 at Standard Biotools, down from $127.1 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $127.1 million in Q1 2026 and troughed at -$76.3 million in Q1 2022.
• A 5-year average of -$19.0 million and a median of -$26.4 million in 2025 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income plunged 305.82% in 2022 and jumped 588.1% in 2026, its largest moves.
• Over 5 years, Consolidated Net Income stood at -$20.8 million in 2022, then jumped by 82.05% to -$3.7 million in 2023, then tumbled by 288.05% to -$14.5 million in 2024, then soared by 232.83% to $19.3 million in 2025, then tumbled by 238.82% to -$26.8 million in 2026.
• The last three Consolidated Net Income figures came in at -$26.8 million (Q2 2026), $127.1 million (Q1 2026), and $19.3 million (Q4 2025), per Business Quant data.